In the realm of modern science, few names resonate as profoundly as Sir Shankar Balasubramanian. Born in Chennai, India, in 1966, and relocating to the UK shortly after, Balasubramanian’s journey from a rural Cheshire upbringing to becoming a Herchel Smith Professor of Medicinal Chemistry at the University of Cambridge is nothing short of inspirational.
His pioneering work in nucleic acids has not only revolutionized genomic sequencing but has also significantly advanced our understanding of epigenetics.
Early Life and Education of Shankar Balasubramanian
Balasubramanian’s early years in the UK laid the foundation for his remarkable scientific career. Educated at Daresbury Primary School and later Appleton Hall High School, his academic journey led him to Fitzwilliam College, Cambridge.
Here, he pursued the Natural Sciences Tripos, earning his undergraduate degree in 1988. His academic rigor and curiosity were further exemplified during his PhD research on the reaction mechanism of the enzyme chorismate synthase, supervised by Chris Abell, which he completed in 1991.
Academic and Professional Ascension
Following his PhD, Balasubramanian expanded his horizons with a stint in the United States as a SERC/NATO Research Fellow at Pennsylvania State University. Working under Stephen J. Benkovic, he honed his research skills, laying the groundwork for his future innovations. In 1994, he returned to the University of Cambridge to commence his independent academic career.
Over the years, he progressed through various roles, from College Lecturer to University Lecturer, Reader in Chemical Biology, and ultimately, Professor of Chemical Biology. His appointment as the Herchel Smith Professor of Medicinal Chemistry in 2008 marked a significant milestone in his career.
Revolutionary Contributions to Genomic Sequencing
Balasubramanian’s work in nucleic acids has had a transformative impact on the field of genomics. He is best known as the principal inventor of Solexa sequencing, a groundbreaking next-generation sequencing technology. This innovation has democratized genomic sequencing, making it more accurate, affordable, and accessible.
Solexa sequencing has not only enabled routine sequencing of human genomes but has also catalyzed numerous advances in biology and medicine. By lowering the barriers to genetic research, Balasubramanian’s invention has opened new avenues for personalized medicine, cancer research, and the understanding of genetic diseases.
Epigenetics and Beyond
In addition to his contributions to genomic sequencing, Shankar Balasubramanian has made significant strides in the study of epigenetics. His research has focused on non-coding genetic elements, particularly G-quadruplexes—four-stranded DNA structures that play critical roles in regulating gene expression.
By elucidating the functions and mechanisms of these structures, Shankar Balasubramanian has advanced our understanding of how genes are controlled and how their misregulation can lead to diseases such as cancer.
Shankar Balasubramanian’s recent work involves the development of novel chemical methods to investigate epigenetic modifications, such as the sequencing of 5-formylcytosine, 5-hydroxymethylcytosine, and 5-methylcytosine.
These modifications are crucial for regulating gene expression and maintaining genomic stability. By pioneering techniques to study these changes at single-base resolution, Balasubramanian’s research is shedding light on the complex interplay between genetics and the environment, offering new insights into disease mechanisms and potential therapeutic targets.
Also Read:Shapurji Saklatvala: A Journey from Bombay to the British Parliament